Upstream Bio Inc Dossier
Qualitative Analysis
Business overview
Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company focused on developing novel therapies for severe inflammatory diseases, with an initial emphasis on respiratory disorders. The company's development efforts are centered on its sole clinical asset, verekitug (UPB-101), a potent recombinant fully human IgG1 monoclonal antibody. Verekitug is the only known antagonist in clinical development that targets and inhibits the thymic stromal lymphopoietin receptor (TSLPR). By binding to the receptor rather than the TSLP cytokine itself, verekitug aims to deliver superior potency and extended dosing intervals (such as once every 12 or 24 weeks) compared to existing therapies. The company is advancing verekitug across three major indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
De-risking and advancing the clinical development of verekitug, a novel recombinant fully human IgG1 monoclonal antibody targeting the TSLP receptor, across core lead indications including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Expected impact: Establishment of verekitug as a highly potent, differentiated biologic therapy with extended dosing intervals (e.g., once every 12 or 24 weeks) compared to existing approved therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Maruho exclusive rights to develop, manufacture, and commercialize verekitug in Japan, while Maruho reimburses Upstream Bio for specified global research and development activities applicable to Japan.
Terms: Maruho is responsible for all development and commercialization expenses in Japan and reimburses Upstream Bio for R&D costs and drug supply. Upstream Bio received $2.8 million and $1.9 million in reimbursements from Maruho during 2025 and 2024, respectively.
Provides Upstream Bio with a worldwide, non-exclusive, sublicensable license to certain intellectual property rights owned by Lonza, the originator of the master cell bank for verekitug.
Terms: Upstream Bio made annual payments of $0.5 million in 2024 and $0.4 million in 2023 to Lonza, with future royalty and fee obligations tied to manufacturing and sales.
Establishes licensing terms and future royalty obligations tied to the development and commercialization of verekitug.
Terms: Creates future royalty and fee obligations; no royalty payments had been made to Regeneron as of late 2025.